2005-004435-22: INCIDENCE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEAMOPHILIA A TREATED WITH OCTANATE |
|
|
| | 3 | 10 | Europe | OCTANATE, OCTANATE 50 UI/ml, poudre et solvant pour solution injectable, OCTANATE 100 UI/ml, poudre et solvant pour solution injectable, OCTANATE 50 UI/ml, poudre et solvant pour solution injectable, OCTANATE 100 UI/ml, poudre et solvant pour solution injectable | OCTAPHARMA AG | Previously untreated patients with severe (FVIII:C<2%) haemophilia A, no inhibitor activity prior to admission, no concomitant therapy with Interferon, patients registered for regular treatment at the study site, informed consent obtained from parent/legal guardian or patient, no previous treatment with FVIII or blood products containing FVIII, no participation in another clinical trial 4 weeks before study start and during the study. | | | | |
2008-008378-29: A survey on the success of inhibitor elimination using individualized concentrate selection and controlled immune tolerance induction |
|
|
| Ongoing | 3 | 15 | Europe | FACTANE 100UI/ml, KOGENATE Bayer 250 UI, HELIXATE NexGen 250 UI, REFACTO 250 UI, ADVATE 250 UI, OCTANATE 500 UI, KOGENATE Bayer 500 UI, KOGENATE Bayer 1000 UI, HELIXATE NexGen 500 UI, HELIXATE NexGen 1000 UI, REFACTO 500 UI, REFACTO 1000 UI, REFACTO 2000 UI, ADVATE 500 UI, ADVATE 1000 UI, ADVATE 1500 UI, OCTANATE 1000 UI, FACTANE 100UI/ml, KOGENATE Bayer 250 UI, HELIXATE NexGen 250 UI, REFACTO 250 UI, ADVATE 250 UI, OCTANATE 500 UI, KOGENATE Bayer 500 UI, KOGENATE Bayer 1000 UI, HELIXATE NexGen 500 UI, HELIXATE NexGen 1000 UI, REFACTO 500 UI, REFACTO 1000 UI, REFACTO 2000 UI, ADVATE 500 UI, ADVATE 1000 UI, ADVATE 1500 UI, OCTANATE 1000 UI | CHU de Saint-Etienne | patients with haemophilia A | | | | |
